January 19, 2012 -- Jiangsu Kanion Pharma has transferred the global ex-China rights for three small molecule oncology drug candidates to a newly formed California startup, NewGen Therapeutics, in exchange for a minority position in NewGen. The CEO of Kanion USA, Wang Shen, is a co-founder and VP of R&D at NewGen. In China, Kanion is known mainly as a TCM company. More details....
Stock Symbol: (SHA: 600557)
